William Blair analyst Matt Larew has maintained their bullish stance on DHR stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Larew has given his Buy rating due to a combination of factors including Danaher’s strong third-quarter performance, which exceeded both his and consensus expectations. The company’s total revenue reached $6.053 billion, surpassing the anticipated $6.016 billion, with notable contributions from the Biotechnology and Diagnostics segments. Biotechnology core revenue grew by 6.5%, driven by high single-digit increases in bioprocessing revenues, while Diagnostics core revenue saw a 3.5% rise, supported by significant growth in clinical diagnostics.
Additionally, Danaher’s adjusted operating margin improved to 27.9%, marking a year-over-year increase and demonstrating effective cost management. Looking forward, the company maintains a positive outlook with a 2025 guidance for low single-digit core revenue growth and reiterated EPS guidance of $7.70 to $7.80. These factors collectively suggest a robust business trajectory, justifying the Buy rating.
In another report released today, Bank of America Securities also maintained a Buy rating on the stock with a $240.00 price target.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year.